RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 64 filers reported holding RA PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $94,582,000 | +7.7% | 1,970,034 | +5.3% | 0.00% | +33.3% |
| Q4 2019 | $87,797,000 | +104.3% | 1,870,793 | +2.9% | 0.00% | +50.0% |
| Q3 2019 | $42,980,000 | -8.6% | 1,817,333 | +16.2% | 0.00% | 0.0% |
| Q2 2019 | $47,033,000 | +60.3% | 1,564,112 | +19.4% | 0.00% | +100.0% |
| Q1 2019 | $29,346,000 | +49.1% | 1,310,146 | +21.1% | 0.00% | 0.0% |
| Q4 2018 | $19,683,000 | +47.2% | 1,081,466 | +46.3% | 0.00% | 0.0% |
| Q3 2018 | $13,374,000 | +98.4% | 739,337 | +9.1% | 0.00% | – |
| Q2 2018 | $6,741,000 | +89.6% | 677,408 | +1.2% | 0.00% | – |
| Q1 2018 | $3,555,000 | +6.7% | 669,573 | +70.9% | 0.00% | – |
| Q4 2017 | $3,331,000 | -36.0% | 391,888 | +9.9% | 0.00% | – |
| Q3 2017 | $5,205,000 | -19.9% | 356,513 | +2.9% | 0.00% | – |
| Q2 2017 | $6,496,000 | +12.9% | 346,602 | +28.3% | 0.00% | – |
| Q1 2017 | $5,753,000 | +279.7% | 270,253 | +170.9% | 0.00% | – |
| Q4 2016 | $1,515,000 | – | 99,775 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |